Monthly Archives: November 2011
Mundipharma commits further $50 million to collaboration with Infinity Pharmaceuticals
Infinity Pharmaceuticals has announced that Mundipharma has committed to providing over $50 million in funding in 2013 for the continued development of IPI-145, Infinity’s oral inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma, as well as development candidates arising out of … Continue reading
Filed under alliances
Antitrust regulators clear Biogen collaboration with Portola Pharmaceuticals
Biogen Idec has announced that federal antitrust regulators cleared its collaboration with Portola Pharmaceuticals on treatments for autoimmune and inflammatory diseases. The collaboration was announced in October. Biogen agreed to pay Portola $36 million upfront and make a $9 million … Continue reading
Filed under alliances
NuCana Biomed has $10.5 million in series A round
NuCana Biomed has $10.5 million in a series A round led by Sofinnova Partners. Morningside Ventures, Scottish Venture Fund and Alida Capital also participated in the fund raising. NuCana has licensed the exclusive, worldwide rights to ProTide technology from Morvus … Continue reading
Filed under funding
Roche, PTC Therapeutics and the SMA Foundation sign $490 million SMA collaboration
Roche, PTC Therapeutics and the SMA Foundation have announced that they have signed a licensing agreement for PTC’s Spinal Muscular Atrophy (SMA) programme. SMA is a genetic neuromuscular disorder that causes muscle weakness. One in every 10,000 children born is … Continue reading
Filed under alliances
Marina Biotech and Debiopharm achieve milestone in bladder cancer program
Marina Biotech has announced that the joint Marina and Debiopharm team has selected and confirmed the lead DiLA2 formulation for a RNAi-based therapy for the treatment of non-muscle invasive bladder cancer. The team has also advanced the lead UsiRNA candidates … Continue reading
Filed under alliances
Rib-X files for $80 million IPO
Rib-X Pharmaceuticals has announced that it has filed a registration statement with the SEC relating to the proposed initial public offering of its common stock worth up to $80 million. In July Rib-X signed a collaboration agreement with Sanofi.
Filed under funding
GVK Biosciences signs collaboration with Temple University
GVK Biosciences has entered into a drug discovery alliance with Philadelphia-based Moulder Center for Drug Discovery Research at Temple University. As part of the drug discovery collaboration, GVK Bio will be responsible for the target validation, lead identification and lead … Continue reading
Filed under alliances
Galena Biopharma signs collaboration with Genentech
Galena Biopharma has announced a clinical development collaboration with Genentech and The Henry M Jackson Foundation for the Advancement of Military Medicine to develop NeuVax in combination with Herceptin in adjuvant breast cancer patients currently not eligible for Herceptin therapy. … Continue reading
Filed under alliances
Rosetta Genomics reported to be facing bankruptcy
Genomeweb reports that Rosetta Genomics is facing bankruptcy, according to documents filed this month with the US Securities and Exchange Commission. According to the reports Rosetta has defaulted on a $650,000 payment it owed to Prometheus Laboratories. The terms of … Continue reading
Filed under bankruptcy
Abbott expands agreement with GlaxoSmithKline Biologicals
Abbott Laboratories has announced that it will expand its existing agreement with GlaxoSmithKline Biologicals to include the development of an additional companion diagnostic test in support of GSK’s cancer immunotherapy research program. The company said that companion diagnostic tests are … Continue reading
Filed under alliances
